In addition, early-phase clinical trials presented at ASCO-GI 2024 indicated that the combination of PD - 1 inhibitors with FOLFOX as first-line treatment is feasible and may further expand the immunotherapy landscape for advanced GC (13). The gene discussed is RPL17; the disease is gastric cancer.